drugset
drugset / Trial / NCT04899570

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

NCT04899570 ↗

Phase 2 Unknown 20 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective single-arm phase II study, and the purpose of this study is to evaluate the efficiency of zanubrutinib combined with R-CHOP regimen in newly diagnosed primary intraocular lymphoma. Progression-free survival (PFS) of the cohort is the primary endpoint.

Timeline

Start
2021-04-01
Primary completion
2023-04-01
Completion
2025-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanubrutinib Small molecule 160 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Epirubicin Small molecule 70 mg/m2 Intravenous
Background Prednisone Other / unclassified 60 mg/m2 Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vindesine Small molecule 4 mg Intravenous

Indications

intravascular large B-cell lymphoma